Document Classification

Section Type: RESULTS

Text: In ATTAIN, mean improvements to month 6 were significantly greater for patients treated with abatacept than for placebo patients in sleep disturbance (11. 3 vs 2. 9, p < 0. 001), sleep adequacy (9. 0 vs 0. 6, p < 0. 05), somnolence (10. 5 vs 1. 6, p < 0. 001) and Sleep Problems Index (SPI) I (9. 5 vs 1. 4, p < 0. 0001) and II (9. 8 vs 2. 1, p < 0. 001) ; mean improvements in AIM to year 1 were statistically significant for sleep disturbance (12. 9 vs 8. 9, p < 0. 05) and SPI I (9. 4 vs 6. 7, p < 0. 05) and II (10. 4 vs 7. 3, p < 0. 05).